Marvel BiosciencesMBCOF +9.60%34 Debt-to-EBITDA is 0.73 as of Apr. 2026. GuruFocus rates MBCOF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 290 Biotechnology companies, Marvel Biosciences ranks worse than 344827.24% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Marvel Biosciences's Debt-to-EBITDA or its related term are showing as below:
MBCOF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.3 Med: -1.11 Max: -0.44
Current: -1.3
During the past 6 years, the highest Debt-to-EBITDA Ratio of Marvel Biosciences was -0.44. The lowest was -1.30. And the median was -1.11.
MBCOF's Debt-to-EBITDA is ranked worse than 100% of 290
companies
in the Biotechnology industry
Industry Median: 1.15
vs MBCOF: -1.30
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Marvel Biosciences Debt-to-EBITDA Related Terms
Marvel Biosciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Marvel Biosciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBCOF vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Marvel Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marvel Biosciences Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Marvel Biosciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Apr. 2026) EBITDA data.
Marvel Biosciences (MBCOF) has a Debt-to-EBITDA of 0.73 as of Apr. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Marvel Biosciences. According to the industry distribution chart, Marvel Biosciences ranks #999999 out of 290 companies in the Biotechnology industry.
Is Marvel Biosciences' Debt-to-EBITDA too high?
Marvel Biosciences' current Debt-to-EBITDA is 0.73. The Biotechnology industry median Debt-to-EBITDA is 1.15. Marvel Biosciences' value of 0.73 is 36.5% below this industry median. Based on the distribution chart, Marvel Biosciences ranks #999999 out of 290 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marvel Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marvel Biosciences ranks #999999 out of 290 companies for Debt-to-EBITDA. This places Marvel Biosciences in the lower half of its industry. The industry median Debt-to-EBITDA is 1.15. Marvel Biosciences' value of 0.73 is 36.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 290 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marvel Biosciences's current Debt-to-EBITDA of 0.73 is 36.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Marvel Biosciences. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marvel Biosciences's current Debt-to-EBITDA is 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current Debt-to-EBITDA of 0.73. The current Debt-to-EBITDA is 0.73 and 36.5% below the Biotechnology industry median of 1.15. Marvel Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current Debt-to-EBITDA is 0.73 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
34GF Score
Get the complete analysis for MBCOF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBCOF has been successfully added to your 
